Nicolas PENEL

Professor of Medical Oncolgy

Université de Lille

France

Has grant

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Internal Medicine

30%

Pharmacotherapy

50%

Oncology

70%

Cancer Biology

30%

Targeted Therapy

30%

Medicine

20%

Sarcoma Research

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Recent Grants

Grant: Close

Phase II – Multicentric, randomized, stratified, double-blind phase III study comparing weekly paclitaxel versus weekly paclitaxel plus bevacizumab in patients with unresectable or metastatic angiosarcoma (Angio-Tax-Plus study)

Open Date: 2010-06-01

Close Date: 2013-06-01

Grant: Close

A multicenter randomized phase II study to evaluate the benefit of chemotherapy plus best supportive care (BSC) versus BSC in patients with metastatic oesophageal cancer (MOEC) of squamous-cell type (SC) (MOEC-SC) who have not experienced disease progression or unacceptable toxicity during a 2 month-course of chemotherapy

Open Date: 2010-06-01

Close Date: 2013-06-01

Grant: Close

Phase II randomised trial to evaluate two strategies: continuing versus intermittent (drug-holiday) trabectedin-regimen in patients with advanced soft tissue sarcoma experiencing response or stable disease after the sixth cycle.

Open Date: 2008-02-08

Close Date: 2011-02-08

Grant: Close

2007: O-MEL-INIB- « Multicentric phase II of imatinib mesylate in patients with metastatic uveal melanoma »

Open Date: 2007-06-01

Close Date: 2010-06-01

Grant: Close

2007: AngioNext- « Multicentric stratified phase II study of sorafenib in patients with metastatic or unresectable angiosarcoma»

Open Date: 2007-06-01

Close Date: 2010-06-01

Nicolas PENEL

Professor of Medical Oncolgy

How do I reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Recent Grants

Articles16

L’oncologie : lieu de stage hospitalier idéal pour la R2C ?

Why do second-cycle medical students choose oncology? A literature overview

Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study

Doit-on prendre en compte le stress informationnel de l’oncologue médical ?

Handling missing covariates in observational studies: an illustration with the assessment of prognostic factors of survival outcomes in soft-tissue or visceral sarcomas in irradiated fields (SIF)

Intracranial Solitary Fibrous Tumour Management: A French Multicentre Retrospective Study

Pain in desmoid‐type fibromatosis: Prevalence, determinants and prognosis value

Why will there never be a randomized trial for NTRK-rearranged tumors?

FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression

Impact of the coronavirus disease 2019 pandemic on sarcoma management in France: a 2019 and 2020 comparison

Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer

Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study

A lesion suspected of being a desmoid tumor in the context of familial adenomatous polyposis should be biopsied

Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours

Shortening the Time Interval for the Referral of Patients With Soft Tissue Sarcoma to Expert Centers Using Mobile Health: Retrospective Study

Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis

Collaborators6

Anthony Turpin

Loïc Lebellec

Camille Tlemsani

Jean-Jacques Lemaire

Peter Grimison

Jae Lyun Lee

How do I reach out?